Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 2,007 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 2,007 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $12.04, for a total value of $24,164.28. Following the completion of the transaction, the insider now owns 39,601 shares of the company’s stock, valued at $476,796.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nurix Therapeutics Stock Performance

NRIX opened at $12.02 on Wednesday. The company has a fifty day moving average of $13.70 and a two-hundred day moving average of $9.83. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $18.12. The stock has a market capitalization of $590.80 million, a price-to-earnings ratio of -4.52 and a beta of 2.06.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -3.15 earnings per share for the current year.

Institutional Trading of Nurix Therapeutics

Several institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC lifted its position in shares of Nurix Therapeutics by 23.2% during the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after buying an additional 601,952 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in Nurix Therapeutics by 176.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after purchasing an additional 440,112 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Nurix Therapeutics by 48.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Nurix Therapeutics by 1,012.4% in the third quarter. GSA Capital Partners LLP now owns 195,420 shares of the company’s stock valued at $1,536,000 after purchasing an additional 177,852 shares during the period. Finally, Kennedy Capital Management LLC increased its stake in shares of Nurix Therapeutics by 192.7% during the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock worth $1,286,000 after purchasing an additional 107,719 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HC Wainwright cut their price target on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Wells Fargo & Company decreased their target price on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Friday, February 16th. Morgan Stanley increased their price target on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, April 9th. Finally, Robert W. Baird raised their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.